美国卫生保健资金管理局(HCFA)最近宣布:在老年医疗保险预付制度中,对使用组织型纤维蛋白溶酶活化剂(TPA)治疗心肌梗塞患者的费用并无特殊改变。 The United States Health Care Fund Administration (HCFA) recently announced that there is no specific change in the cost of using tissue-type plasminogen activator (TPA) in the treatment of patients with myocardial infarction in the pre-payment system for senior medical insurance.